Genetic variants in lncRNA SRA and risk of breast cancer
Metrics: PDF 1392 views | HTML 2736 views | ?
Rui Yan1, Kaijuan Wang1,2, Rui Peng1, Shuaibing Wang1, Jingjing Cao1, Peng Wang1,2, Chunhua Song1,2
1Department of Epidemiology and Statistics, College of Public Health, Zhengzhou University, Zhengzhou, 450001, PR China
2Department of Tumor Epidemiology, Henan Key Laboratory of Tumor Epidemiology, Zhengzhou, 450001, PR China
Chunhua Song, e-mail: [email protected]
Keywords: breast cancer, SRA, lncRNA, genetic susceptibility, interaction
Received: December 21, 2015 Accepted: February 21, 2016 Published: March 8, 2016
Long non-coding RNA (lncRNA) steroid receptor RNA activator (SRA) has been identified to activate steroid receptor transcriptional activity and participate in tumor pathogenesis. This case-control study evaluated the association between two haplotype tagging SNPs (htSNPs) (rs10463297, rs801460) of the whole SRA sequence and breast cancer risk. We found that rs10463297 TC genotype significantly increased BC risk compared with CC genotype in both the codominant (TC vs. TT: OR=1.43, 95 % CI=1.02–2.00) and recessive (TC+CC vs. TT: OR=1.39, 95 % CI=1.01–1.92) genetic models. Both TC, TC + CC genotypes of rs10463297 and GA, AA, GA+AA genotypes of rs801460 were significantly associated with estrogen receptor (ER) positivity status. rs10463297 TC (2.09 ± 0.41), CC (2.42 ± 0.51) and TC + CC (2.20 ± 0.47) genotypes were associated with higher blood plasma SRA mRNA levels compared with the TT genotype(1.45 ± 0.34). Gene–reproductive interaction analysis presented a best model consisted of four factors (rs10463297, age, post-menopausal, No. of pregnancy), which could increase the BC risk with 1.58-fold (OR=1.58, 95 % CI=1.23–2.03). These findings suggest that SRA genetic variants may contribute to BC risk and have apparent interaction with reproductive factors in BC progression.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.